Cancer stem cells: landscape, challenges and emerging therapeutic innovations

Area of Science:

• Oncology
• Cancer Biology
• Metabolic Pathways

Background:

• Cancer stem cells (CSCs) are a crucial subpopulation driving tumor initiation, metastasis, and therapy resistance.
• CSCs exhibit remarkable plasticity, enabling survival under metabolic stress and interaction with the tumor microenvironment.
• Recent advances in multiomics and single-cell technologies have deepened our understanding of CSC heterogeneity and metabolism.

Purpose of the Study:

• To review the latest advancements in cancer stem cell (CSC) biology, focusing on metabolic adaptability and therapy resistance.
• To highlight current challenges in CSC research, including biomarker identification and targeted therapy development.
• To explore future perspectives and emerging strategies for effective CSC-directed cancer therapies.

Main Methods:

• Review of recent literature on CSC biology, metabolism, and therapeutic strategies.
• Integration of findings from single-cell sequencing, spatial transcriptomics, and multiomics studies.
• Analysis of emerging technologies like 3D organoid models, CRISPR screens, and AI-driven multiomics.

Main Results:

• CSCs display significant metabolic plasticity, switching fuel sources (glycolysis, oxidative phosphorylation, glutamine, fatty acids) to adapt to diverse conditions.
• Metabolic symbiosis with tumor microenvironment components (stromal, immune, vascular cells) enhances CSC survival and drug resistance.
• Despite progress, challenges persist, including the lack of specific CSC biomarkers and the difficulty of targeting CSCs selectively.

Conclusions:

• Targeting CSCs requires innovative strategies that address their metabolic plasticity and interactions within the tumor microenvironment.
• Emerging approaches like dual metabolic inhibition, synthetic biology, and immunotherapies show promise for overcoming CSC-mediated resistance.
• An integrative approach combining metabolic reprogramming, immunomodulation, and targeted CSC vulnerability inhibition is essential for clinical translation.